160 related articles for article (PubMed ID: 11327712)
21. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Mills DC; Puri R; Hu CJ; Minniti C; Grana G; Freedman MD; Colman RF; Colman RW
Arterioscler Thromb; 1992 Apr; 12(4):430-6. PubMed ID: 1558834
[TBL] [Abstract][Full Text] [Related]
22. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
23. Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure.
Schäfer A; Fraccarollo D; Pförtsch S; Loch E; Neuser J; Vogt C; Bauersachs J
Basic Res Cardiol; 2011 May; 106(3):485-94. PubMed ID: 21287353
[TBL] [Abstract][Full Text] [Related]
24. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
VAN Giezen JJ; Nilsson L; Berntsson P; Wissing BM; Giordanetto F; Tomlinson W; Greasley PJ
J Thromb Haemost; 2009 Sep; 7(9):1556-65. PubMed ID: 19552634
[TBL] [Abstract][Full Text] [Related]
25. A novel method for chemical modification of functional groups other than a carboxyl group in proteins by N-ethyl-5-phenylisooxazolium-3'-sulfonate (Woodward's reagent-K): inhibition of ADP-induced platelet responses involves covalent modification of aggregin, an ADP receptor.
Puri RN; Colman RW
Anal Biochem; 1996 Sep; 240(2):251-61. PubMed ID: 8811919
[TBL] [Abstract][Full Text] [Related]
26. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
Tanaka KA; Szlam F; Kelly AB; Vega JD; Levy JH
Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
[TBL] [Abstract][Full Text] [Related]
27. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production.
Cattaneo M; Lombardi R; Zighetti ML; Gachet C; Ohlmann P; Cazenave JP; Mannucci PM
Thromb Haemost; 1997 May; 77(5):986-90. PubMed ID: 9184415
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
29. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
30. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Neubauer H; Lask S; Engelhardt A; Mügge A
Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
[TBL] [Abstract][Full Text] [Related]
31. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
32. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets.
Mateos-Trigos G; Evans RJ; Heath MF
Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014
[TBL] [Abstract][Full Text] [Related]
33. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R
Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380
[TBL] [Abstract][Full Text] [Related]
34. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of the human P2Y13 receptor.
Marteau F; Le Poul E; Communi D; Communi D; Labouret C; Savi P; Boeynaems JM; Gonzalez NS
Mol Pharmacol; 2003 Jul; 64(1):104-12. PubMed ID: 12815166
[TBL] [Abstract][Full Text] [Related]
37. The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor.
Jin J; Tomlinson W; Kirk IP; Kim YB; Humphries RG; Kunapuli SP
Br J Pharmacol; 2001 Jun; 133(4):521-8. PubMed ID: 11399669
[TBL] [Abstract][Full Text] [Related]
38. The platelet P2 receptors in thrombosis.
Gachet C; Hechler B
Semin Thromb Hemost; 2005 Apr; 31(2):162-7. PubMed ID: 15852219
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
40. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
